Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Witte, K.
Right arrow Articles by Haller, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Witte, K.
Right arrow Articles by Haller, C.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes 53:2640-2644, 2004
© 2004 by the American Diabetes Association, Inc.

Nitric Oxide–Sensitive Soluble Guanylyl Cyclase Activity Is Preserved in Internal Mammary Artery of Type 2 Diabetic Patients

Klaus Witte1, Jochen Hachenberger1, Maria F. Castell2, Christian F. Vahl2, and Christlieb Haller3

1 Faculty of Clinical Medicine Mannheim, Institute of Pharmacology and Toxicology, University of Heidelberg, Mannheim, Germany
2 Department of Thoracic Surgery, University of Heidelberg, Heidelberg, Germany
3 Department of Internal Medicine III, University of Heidelberg, Heidelberg, Germany

Vascular reactivity to nitric oxide (NO) is mediated by NO-sensitive soluble guanylyl cyclase (sGC). Since a diminished activity of vascular sGC has been reported in an animal model of type 2 diabetes, the sGC activity was assayed in vitro in internal mammary artery specimens obtained during bypass surgery from patients with and without type 2 diabetes. The sensitivity of sGC to NO, which is dependent on Fe2+-containing heme, was measured in vitro using stimulation with diethylamine NONOate (DEA/NO). In addition, the novel cyclic guanosine monophosphate–elevating compound HMR-1766 was used to test the stimulation of the oxidized heme-Fe3+–containing form of sGC. Basal activity of sGC and its sensitivity to stimulation by DEA/NO and HMR-1766 were not different between control and type 2 diabetic patients: maximum stimulation by DEA/NO amounted to 475 ± 67 and 418 ± 59 pmol · mg–1 · min–1 in control and type 2 diabetic patients, respectively. The maximum effects of HMR-1766 were 95 ± 18 (control subjects) and 83 ± 11 pmol · mg–1 · min–1 (type 2 diabetic patients). Hypertension, hyperlipidemia, drug treatment with statins, ACE inhibitors, or nitrates had no effect on sGC activity. In conclusion, the present findings do not support the hypothesis that desensitization of sGC contributes to the pathogenesis of diabetic vascular dysfunction in humans.

Address correspondence and reprint requests to Dr. Christlieb Haller, Medizinische Klinik I, Hegau-Klinikum Singen, Virchowstr. 10, 78221 Singen, Germany. E-mail: christlieb.haller{at}hegau-klinikum.de


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Mol. Pharmacol.Home page
U. Schindler, H. Strobel, K. Schonafinger, W. Linz, M. Lohn, P. A. Martorana, H. Rutten, P. W. Schindler, A. E. Busch, M. Sohn, et al.
Biochemistry and Pharmacology of Novel Anthranilic Acid Derivatives Activating Heme-Oxidized Soluble Guanylyl Cyclase
Mol. Pharmacol., April 1, 2006; 69(4): 1260 - 1268.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2004 by the American Diabetes Association.